Posts tagged "Combination"

Phase IIIb Comparison of BARACLUDE

Phase IIIb Comparison of BARACLUDE® (entecavir) Monotherapy versus BARACLUDE plus Tenofovir Combination Shows No Statistical Difference Between Study Arms

San Francisco, CA (PRWEB) November 09, 2011

Bristol-Myers Squibb Company (NYSE: BMY) today announced 96-week results from the BE‐LOW™ study, a Phase IIIb clinical trial comparing BARACLUDE monotherapy (0.5mg once daily) with BARACLUDE (0.5mg once daily) plus tenofovir (300mg once daily) in treatment-naïve adult patients with HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) with compensated liver disease. In this study, no statistically significant difference was observed between the two treatment arms in the primary efficacy endpoint of HBV DNA

“In these 96-week data comparing entecavir monotherapy to combination of entecavir plus tenofovir, we found that combination therapy did not result in statistically significant difference in virologic response compared to entecavir monotherapy. The BE-LOW study data confirmed the results of previous studies showing limited or no benefit of combination therapy compared to monotherapy for treatment-naïve patients with chronic hepatitis B,” said principal investigator Anna Lok, MD, FRCP, director of clinical hepatology and professor in the department of internal medicine at the University of Michigan Medical School in Ann Arbor.

Study Results

In this study, 379 nucleos(t)ide-naïve patients with CHB were randomized to receive either BARACLUDE (entecavir) 0.5 mg once daily (n=182) or BARACLUDE 0.5 mg plus tenofovir 300 mg once daily (n=197). Key findings at week 96 are:

A comparable proportion of patients in both treatment arms achieved the primary efficacy endpoint of HBV DNA
Among HBeAg-positive patients, the proportion achieving HBV DNA
Among HBeAg-negative patients, the proportion achieving HBV DNA

Secondary efficacy endpoints measured in the study included alanine aminotransferase (ALT) normalization, HBeAg seroconversion, and HBeAg loss. ALT normalization was observed in 81.9% (149/182) of patients in this study in the BARACLUDE (entecavir) monotherapy arm versus 69% (136/197) in the BARACLUDE plus tenofovir arm. HBeAg seroconversion was observed in 32.5% (41/126) of patients in the BARACLUDE (entecavir) monotherapy arm versus 21.7% (30/138) in the BARACLUDE plus tenofovir arm in this study.

Two patients (1.1%) in the BARACLUDE monotherapy arm compared to five patients (2.5%) in the BARACLUDE plus tenofovir arm discontinued treatment prior to week 96. Patients who discontinued therapy prior to week 96 were considered treatment failures.

The overall adverse event profiles were similar across study arms. A total of three deaths occurred among treated patients, all on the BARACLUDE plus tenofovir arm: one due to bile duct tumor; one due to a late-onset exacerbation of hepatitis which was associated with breakthrough viremia while on continued treatment; and one due to cardiac arrest. One patient (0.5%) in the BARACLUDE monotherapy arm and two patients (1.0%) in the BARACLUDE plus tenofovir arm experienced on treatment ALT flares, defined as greater than 2 x baseline ALT and greater than 10 x ULN. No patients (0.0%) in either arm experienced off-treatment ALT flares. Six patients (3.3%) in the BARACLUDE monotherapy arm and four (2.0%) patients in the BARACLUDE plus tenofovir arm experienced serum creatinine increase ≥0.3 mg/dL. A total of five malignancies occurred among patients in the study: four (2.2%) patients in the BARACLUDE monotherapy arm and one (0.5%) patient in the BARACLUDE plus tenofovir arm. In the BARACLUDE monotherapy arm, there were three diagnoses of hepatocellular carcinoma (two on-treatment and one off-treatment) and one case of gastric cancer. In the BARACLUDE plus tenofovir arm there was one case of breast cancer.

Two patients (1.0%) in the BARACLUDE monotherapy arm and seven patients (3.6%) in the BARACLUDE plus tenofovir arm experienced virologic breakthrough. No recognized genotypic resistance mutations were observed in either treatment arm.

About The Study

The BE-LOW study is an open-label, multicenter, Phase IIIb study of 379 nucleos(t)ide-naïve patients with CHB. The patients were randomized 1:1 and treated with either BARACLUDE 0.5 mg once daily (n=182) or BARACLUDE 0.5 mg plus tenofovir 300 mg once daily (n=197). Nucleos(t)ide-naïve, HBeAg-negative CHB patient enrollment was capped at 30%. The primary efficacy endpoint was the proportion of patients with HBV DNA

About Chronic Hepatitis B

Approximately 350 million people worldwide are chronically infected with hepatitis B (approximately 5% of the world’s population) and 75% of these cases occur in the Asia-Pacific region.(2) Most people with chronic hepatitis B show no signs or symptoms, so many of those chronically infected are unaware of their status. A blood test can diagnose chronic hepatitis B. Patients should speak with their doctor about options available for this condition.

About BARACLUDE®

Discovered at Bristol-Myers Squibb, BARACLUDE® is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:

compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis

decompensated liver disease

For full prescribing information for BARACLUDE®, please consult the Summary of Product Characteristics.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.

BARACLUDE® (entecavir) is a registered trademark of Bristol-Myers Squibb Company.

Contacts:             

Bristol-Myers Squibb

Media: Annie Simond, +33 1 58 83 65 66, annie.simond(at)bms(dot)com

Note:

(1) HBV DNA carries the genetic blueprint of the hepatitis B virus. The number of HBV DNA “copies” found in a person’s blood, or “viral load,” indicates how rapidly the virus is reproducing in their liver. Low levels of HBV DNA, recognized as 300 copies per milliliter or less, indicate an “inactive” hepatitis B infection.

Reference:

(2) Hou J, Liu Z, Gu F. Epidemiology and Prevention of Hepatitis B Virus Infection. Int J Med Sci 2005; 2:50 – 57. Available from http://www.medsci.org/v02p0050.htm Accessed November 2011

###

©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Related Breast Cancer Prevention Press Releases

Winning Edge Designs Breast Cancer Prevention Rose Head Cover
Breast Cancer Prevention Rose 460cc Golf Headcover Nice…

Day-timer Products – Desk Calendar Refill, 2PPD, 2-Hole Punched, 3-1/2″x6″ – Sold as 1 EA – Show your support for breast cancer research with a Pink Ribbon Desk Calendar Refill. Day-Timer contributes 10 percent of the proceeds to The Breast Cancer Research Foundation to achieve the prevention and cure of breast cancer. Pink Ribbon design on white 3-1/2″ x 6″ pages coordinates with other Pink Ribbon products. Each two-page-per-day offers hourly appointment times from 7 AM to 5 PM and past, curren
Day-timer Products – Desk Calendar Refill, 2PPD, 2-Hole Punched, 3-1/2″x6″ – Sold as 1 EAShow your support for breast cancer re…

Breast Cancer: Risks and Prevention, Diagnosis & Treatments
What are the risk factors for breast cancer and what decisions will a woman need to make on the basis of an abnormal mammogram res…

Combination Therapy May Help Some Patients with Advanced Breast Cancer

A combination of two available cancer drugs could offer a new treatment option for postmenopausal women whose advanced breast cancer has stopped responding to hormonal therapy, researchers said last week at a scientific meeting in Stockholm, Sweden.
NCI Cancer Bulletin

Breast Cancer Pink Ribbon Coffee Mug (Butterfly design)-Retail
This is a beautiful pink ribbon coffee mug. It is a white mug with a pink ribbon as a butterfly. The butterfly is surrounded by fl…

Breast Cancer Pink Ribbon Stickers (Make A Difference design)
These We Can Make A Difference pink ribbon stickers are 2.0″ in diameter and have 500 stickers on each roll. Comes in an easy dist…

Linda Murray Breast Cancer Support Lifelike Baby Doll: Crawl For The Cause by Ashton Drake
Breast Cancer Support Doll Crawls for the Cause! Lifelike RealTouch(R) Baby Doll by Master Doll Artist Linda Murray! – Women every…

For Hard-To-Treat Cancers, Novel Drug Combination Offers Therapeutic Promise

Researchers at Brigham and Women’s Hospital (BWH) have identified a new combination of targeted therapies that, together, may treat two aggressive tumor types that until now have not had effective treatments. These findings are published in Cancer Cell on September 13, 2011. While numerous anti-cancer drugs are being developed, many tumors do not respond to currently available single therapies…
Cancer / Oncology News From Medical News Today

Baden National Breast Cancer Foundation Pink Mini Volleyball
Show your support for the National Breast Cancer Foundation with this Baden Micro Mini Pink Volleyball. This is a great ball for j…

Keep-A-Breast 1 Inch I Love Boobies Bracelet Black/White
By purchasing this product from the merchant LOSERKIDS only, you are supporting The Keep A Breast Foundation. 100% of the net proc…

Alpen National Breast Cancer Foundation 8 x 25 Wide Angle Porro Prism Compact Binocular
Alpen Optics is the first optics company to partner with the National Breast Cancer Foundation with our new Pink Series Binocular …

Master Lock 8161DPNK Breast Cancer Research Foundation Combination Cable Bike Lock, 6 Feet x 3/8 Inch, Pink

Master Lock 8161DPNK Breast Cancer Research Foundation Combination Cable Bike Lock, 6 Feet x 3/8 Inch, Pink

• Ultra high cable performance
• Set your own combination lock
• Integrated lock and body
• 6′ (1.8m) by 3/8″ (10mm) self coiling braided steel cable
• Ideal for bicycles, skateboards and sports equipment

List Price: $ 14.84

Price:

Combination antibody therapy shows promise in metastatic melanoma

A duo of monoclonal antibodies — ipilimumab and bevacizumab — each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase 1 clinical trial.
ScienceDaily: Cancer News

21st Century Understanding Cancer Toolkit: Life After Cancer Treatment, Valuable Advice and Support for Patients, Survivors, Families, Parents, Children, Caregivers, Young People, Advanced Cancer
This massive compendium, with over 400 pages and eleven chapters, has authoritative information and practical advice from the nati…

Breast Cancer 101 C101 Basics for the Diagnosed A planner for people with Cancer & their Caregivers

Surviving Your Wife’s Cancer: A Guide For Husbands Whose Wives Have Been Diagnosed With Cancer
Stan Scott lost his wife to sarcoma in 1991. Realizing that many men were going through the same emotional and physical trauma he …

AVEO’s Ficlatuzumab In Combination With Gefinitib Well Tolerated In Patients With Non-Small Cell Lung Cancer; Phase 1b Data Presented At ASCO

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced results from the Phase 1b portion of its Phase 1b/2 clinical study of ficlatuzumab in combination with gefitinib (Iressa(TM)) in Asian subjects with non-small cell lung cancer (NSCLC)…
Cancer / Oncology News From Medical News Today

Bond 6928 Pink 50-Foot Medium Duty Garden Hose With Free 9 Pattern Nozzle
Medium duty garden hose with 9 pattern watering nozzle. 5/8 diameter hose is flexible and easy to coil in all weather. Double spir…

Master Lock 146T Breast Cancer Research Foundation Padlock, Pink 2-Pack
Specification:Shackle Diameter: 1/4″Vertical Clearance: 7/8″Horizontal Clearance: 13/16″Key Types Available: 2-pack keyed alike Fe…

Mobile Edge Komen Eco-Friendly Tote, Black w ithPink Trim (Fits 16-Inch Laptops)
The Mobile Edge Komen ECO Laptop Tote is the perfect bag for a new generation. A full-featured laptop case with a removable comput…

Combination Cancer Therapy

Combination Cancer Therapy

Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient’s bedside for the future treatments in cancer therapy.

Price: $ 1.99
Sold by Buy.com

Combination Overcomes Breast Cancer Resistance To Herceptin

Combination Overcomes Breast Cancer Resistance To Herceptin
Breast cancer tumors take numerous paths to resist the targeted drug Herceptin, but a single roadblock at a crucial crossroads may restore a tumor’s vulnerability to treatment, scientists at The University of Texas MD Anderson Cancer Center report on line at Nature Medicine. Adding the drug saracatinib to Herceptin treatment shrinks previously resistant tumors by cutting off at least five …
Read more on Medical News Today

Combination overcomes breast cancer resistance to herceptin
Breast cancer tumors take numerous paths to resist the targeted drug Herceptin, but a single roadblock at a crucial crossroads may restore a tumor’s vulnerability to treatment, scientists report.
Read more on Science Daily

Cancer: Symptoms & Treatment History (1940s) [DVD]
Cancer is an interesting short film that explains the signs and symptoms of cancer and its treatment. It features Mr. Bert Marshal…

Anti-breast cancer drug testing
As deeper mouse model mimics original human cancer biology as more satisfactory experimental drug testing would predict it’s effic…

Breast cancer drug under tough scrutiny.(Health): An article from: Winnipeg Free Press
This digital document is an article from Winnipeg Free Press, published by Thomson Gale on October 30, 2007. The length of the art…